Market Overview

UPDATE: FDA Advisory Committee Recommends Approval of HETLIOZ


Vanda Pharmaceuticals (NASDAQ: VNDA) announced Thursday that the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee (Advisory Committee) voted overwhelmingly to recommend the approval of Vanda's New Drug Application (NDA) for tasimelteon, proposed tradename HETLIOZ™, for the treatment of Non-24-Hour Disorder (Non-24) in the totally blind. 

The advisory panel found that:

Non-24 is an appropriate indication for an FDA-approved therapy;
the clinical endpoints are appropriate to support the indication;
there is substantial evidence of tasimelteon efficacy in Non-24; and
and the safety of tasimelteon in Non-24 has been adequately addressed.
"We are extremely pleased that the FDA's advisory committee has recommended that the FDA approve HETLIOZ™ for the treatment of Non-24 in the totally blind," said Mihael H. Polymeropoulos M.D., Vanda's President and Chief Executive Officer. "We are now one step closer toward our goal of providing a treatment option that addresses the physiologic cause of this serious, debilitating orphan condition that impacts a majority of totally blind individuals."

Vanda's tasimelteon NDA is currently under Priority Review by the FDA for the treatment of Non-24 in the

See full press release

Posted-In: News Guidance Offerings Contracts FDA Management Global


Related Articles (VNDA)

View Comments and Join the Discussion!

Partner Center